Protective Effects of Cytomegalovirus DNA Copies ≧1000/mL for AML Patients in Complete Remission After Single Cord Blood Transplantation

References

• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. N Engl J Med. 2014;371(4):339–348. doi:10.1056/NEJMsa131170725054717
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Ruggeri A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood–a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107–117.26445106
   PubMed Web of Science ®Google Scholar
• Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491–498. doi:10.1182/blood-2013-02-45317523673863
   PubMed Web of Science ®Google Scholar
• Brunstein CG. Umbilical cord blood transplantation for the treatment of hematologic malignancies. Cancer Control. 2011;18(4):222–236. doi:10.1177/10732748110180040321976241
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–e27. doi:10.1016/S2352-3026(15)00289-626947200
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78–83.16434374
   PubMed Web of Science ®Google Scholar
• Broers AEC, Holt R, Esser J, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation. Blood. 2000;95(7):2240–2245. doi:10.1182/blood.V95.7.224010733491
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–5719. doi:10.1182/blood-2008-10-14356019299333
   PubMed Web of Science ®Google Scholar
• Ramanathan M, Teira P, Battiwalla M, et al. Impact of early CMV reactivation in cord blood stem cell recipients in the current era. Bone Marrow Transplant. 2016;51(8):1113–1120. doi:10.1038/bmt.2016.8927042847
   PubMed Web of Science ®Google Scholar
• Peric Z, Wilson J, Durakovic N, et al. Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53(6):1450–1456. doi:10.1038/s41409-018-0172-y29662245
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013;122(7):1316–1324. doi:10.1182/blood-2013-02-48707423744585
   PubMed Web of Science ®Google Scholar
• Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant. 2014;20(1):46–52. doi:10.1016/j.bbmt.2013.10.00324120526
   PubMed Web of Science ®Google Scholar
• Takenaka K, Nishida T, Asano-Mori Y, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for hematopoietic cell transplantation transplantation-related complication working group. Biol Blood Marrow Transplant. 2015;21(11):2008–2016. doi:10.1016/j.bbmt.2015.07.01926211985
   PubMed Web of Science ®Google Scholar
• Xiebing Bao QZ, Shengli X, Xiaohui H, et al. Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen. Am J Transl Res. 2016;8:653–661.27158357
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Lindemann M, Opalka B, Bauer S, Ross RS, Elmaagacli AH. Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function. Leuk Lymphoma. 2015;56(11):3189–3197. doi:10.3109/10428194.2015.103296825818505
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016;30(2):456–463. doi:10.1038/leu.2015.26026416461
   PubMed Web of Science ®Google Scholar
• Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665–2674. doi:10.1182/blood-2011-10-38699522180440
   PubMed Web of Science ®Google Scholar
• Scheper W, van Dorp S, Kersting S, et al. GammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia. 2013;27(6):1328–1338. doi:10.1038/leu.2012.37423277330
   PubMed Web of Science ®Google Scholar
• Knight A, Madrigal AJ, Grace S, et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116(12):2164–2172. doi:10.1182/blood-2010-01-25516620576814
   PubMed Web of Science ®Google Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438. doi:10.1182/blood-2015-11-67963926884374
   PubMed Web of Science ®Google Scholar
• Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–1338. doi:10.1182/blood-2014-10-60903225593335
   PubMed Web of Science ®Google Scholar
• Humar A, Michaels M, Monitoring A. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–274. doi:10.1111/j.1600-6143.2005.01207.x16426310
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828.7581076
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956. doi:10.1016/j.bbmt.2005.09.00416338616
   PubMed Web of Science ®Google Scholar
• Sun Z, Liu H, Luo C, et al. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study. Int J Cancer. 2018;143(3):699–708. doi:10.1002/ijc.v143.329473150
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633. doi:10.1016/j.bbmt.2009.07.00419896087
   PubMed Web of Science ®Google Scholar
• Network NCC. Acute myeloid leukemia, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw.
   Google Scholar
• BD C, PA C, DR H, Head DR. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5):813–819. doi:10.1200/JCO.1990.8.5.8132185339
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Lim Y-J, Kim J-Y, Kim Y-D, Lee S-W. Pre-engraftment syndrome in hematopoietic stem cell transplantation. J Korean Med Sci. 2008;23(1):98–103. doi:10.3346/jkms.2008.23.1.9818303207
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87–91. doi:10.1093/cid/ciw66827682069
   PubMed Web of Science ®Google Scholar
• Tong J, Sun Z, Liu H, et al. Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China. Chin J Cancer Res. 2013;25(6):695–703. doi:10.3978/j.issn.1000-9604.2013.11.0824385697
   PubMed Web of Science ®Google Scholar
• Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78(11):1085–1103.29961185
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–213. doi:10.1002/rmv.v20:420564615
   PubMed Web of Science ®Google Scholar
• Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–3738. doi:10.1200/JCO.2010.28.885220625136
   PubMed Web of Science ®Google Scholar
• Hemmati PG, Terwey TH, Na IK, et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome. Eur J Haematol. 2015;95(6):498–506. doi:10.1111/ejh.1252225598394
   PubMed Web of Science ®Google Scholar
• Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP. Br J Haematol. 2019;186:e65–e115. doi:10.1111/bjh.1592730924125
   PubMed Web of Science ®Google Scholar
• Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530–1538. doi:10.1200/JCO.2012.45.024723478054
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–1412. doi:10.1182/blood-2010-08-30412121540462
   PubMed Web of Science ®Google Scholar
• Horwitz ME. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol. 2011;23(2):197–202. doi:10.1097/CCO.0b013e328342b82a21252669
   PubMed Web of Science ®Google Scholar
• Weisdorf DJ. Reduced-intensity versus myeloablative allogeneic transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):321–326. doi:10.1016/j.hemonc.2017.05.00228641099
   PubMedGoogle Scholar
• Qiu Z, Huang H, Grenier JM, et al. Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8(+) T-cell response and protects mice from melanoma. Cancer Immunol Res. 2015;3(5):536–546. doi:10.1158/2326-6066.CIR-14-004425633711
   PubMed Web of Science ®Google Scholar
• Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113(6):1387–1395. doi:10.1002/cncr.2371218671239
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen X, Rong G, et al. Peripheral blood lymphocyte responses to cytomegalovirus seropositivity after allogeneic-hematopoietic stem cell transplantation. Onco Targets Ther. 2018;11(2):5143–5150. doi:10.2147/OTT30210235
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Varanasi PR, Ogonek J, et al. Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation. PLoS One. 2019;14(3):e0213739. doi:10.1371/journal.pone.021373930889204
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Koldehoff M, Lindemann M, et al. Response: T cells are required for the CMV-induced antileukemia effect after transplant. Blood. 2012;119:1090–1091. doi:10.1182/blood-2011-11-386821
   Web of Science ®Google Scholar
• Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944–953. doi:10.1056/NEJMoa160207427602666
   PubMed Web of Science ®Google Scholar